COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability—putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2020-12-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://www.actamedindones.org/index.php/ijim/article/view/1648 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850072479735742464 |
|---|---|
| author | Youdiil Ophinni Anshari Saifuddin Hasibuan Alvina Widhani Suzy Maria Sukamto Koesnoe Evy Yunihastuti Teguh H Karjadi Iris Rengganis Samsuridjal Djauzi |
| author_facet | Youdiil Ophinni Anshari Saifuddin Hasibuan Alvina Widhani Suzy Maria Sukamto Koesnoe Evy Yunihastuti Teguh H Karjadi Iris Rengganis Samsuridjal Djauzi |
| author_sort | Youdiil Ophinni |
| collection | DOAJ |
| description |
The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability—putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all of Southeast Asia. One hope remains in the groundbreaking universal effort in search of a vaccine against the causative virus SARS-CoV-2, which has shown success unparalleled in human vaccine development thus far. An array of modalities including novel techniques are being utilized as vaccine platforms, with the closest to phase III clinical trial completion being mRNA (manufactured by Moderna and BioNTech/Pfizer), inactivated virus (Sinovac, Sinopharm), viral vector (Oxford/AstraZeneca, Gamaleya, Janssen/Johnson&Johnson, CanSino), and protein subunit (Novavax). The vaccine produced by BioNTech/Pfizer has been deployed to the public as the first ever licensed COVID-19 vaccine. In this review, we will review all of these modalities on their safety and immunogenicity, phase II/III trial results of the nine vaccine candidates and current situation as of 29 December 2020, as well as the implication for use and distribution in Indonesia. COVID-19 vaccine progress, however, is moving exceedingly fast and new advances are unfolding on a daily basis, to which we hope an update to this review can be published in early 2021.
|
| format | Article |
| id | doaj-art-06d7cdeb69ea412a8da7a301852d0fd6 |
| institution | DOAJ |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2020-12-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-06d7cdeb69ea412a8da7a301852d0fd62025-08-20T02:47:04ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322020-12-01524COVID-19 Vaccines: Current Status and Implication for Use in IndonesiaYoudiil Ophinni0Anshari Saifuddin Hasibuan1Alvina Widhani2Suzy Maria3Sukamto Koesnoe4Evy Yunihastuti5Teguh H Karjadi6Iris Rengganis7Samsuridjal Djauzi8Ragon Institute of MGH, MIT and Harvard — Harvard Medical School, Cambridge, MA, United StatesDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo Hospital, Jakarta, Indonesia The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability—putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all of Southeast Asia. One hope remains in the groundbreaking universal effort in search of a vaccine against the causative virus SARS-CoV-2, which has shown success unparalleled in human vaccine development thus far. An array of modalities including novel techniques are being utilized as vaccine platforms, with the closest to phase III clinical trial completion being mRNA (manufactured by Moderna and BioNTech/Pfizer), inactivated virus (Sinovac, Sinopharm), viral vector (Oxford/AstraZeneca, Gamaleya, Janssen/Johnson&Johnson, CanSino), and protein subunit (Novavax). The vaccine produced by BioNTech/Pfizer has been deployed to the public as the first ever licensed COVID-19 vaccine. In this review, we will review all of these modalities on their safety and immunogenicity, phase II/III trial results of the nine vaccine candidates and current situation as of 29 December 2020, as well as the implication for use and distribution in Indonesia. COVID-19 vaccine progress, however, is moving exceedingly fast and new advances are unfolding on a daily basis, to which we hope an update to this review can be published in early 2021. https://www.actamedindones.org/index.php/ijim/article/view/1648vaccineCOVID-19Indonesia |
| spellingShingle | Youdiil Ophinni Anshari Saifuddin Hasibuan Alvina Widhani Suzy Maria Sukamto Koesnoe Evy Yunihastuti Teguh H Karjadi Iris Rengganis Samsuridjal Djauzi COVID-19 Vaccines: Current Status and Implication for Use in Indonesia Acta Medica Indonesiana vaccine COVID-19 Indonesia |
| title | COVID-19 Vaccines: Current Status and Implication for Use in Indonesia |
| title_full | COVID-19 Vaccines: Current Status and Implication for Use in Indonesia |
| title_fullStr | COVID-19 Vaccines: Current Status and Implication for Use in Indonesia |
| title_full_unstemmed | COVID-19 Vaccines: Current Status and Implication for Use in Indonesia |
| title_short | COVID-19 Vaccines: Current Status and Implication for Use in Indonesia |
| title_sort | covid 19 vaccines current status and implication for use in indonesia |
| topic | vaccine COVID-19 Indonesia |
| url | https://www.actamedindones.org/index.php/ijim/article/view/1648 |
| work_keys_str_mv | AT youdiilophinni covid19vaccinescurrentstatusandimplicationforuseinindonesia AT ansharisaifuddinhasibuan covid19vaccinescurrentstatusandimplicationforuseinindonesia AT alvinawidhani covid19vaccinescurrentstatusandimplicationforuseinindonesia AT suzymaria covid19vaccinescurrentstatusandimplicationforuseinindonesia AT sukamtokoesnoe covid19vaccinescurrentstatusandimplicationforuseinindonesia AT evyyunihastuti covid19vaccinescurrentstatusandimplicationforuseinindonesia AT teguhhkarjadi covid19vaccinescurrentstatusandimplicationforuseinindonesia AT irisrengganis covid19vaccinescurrentstatusandimplicationforuseinindonesia AT samsuridjaldjauzi covid19vaccinescurrentstatusandimplicationforuseinindonesia |